SECOND
Amended and Restated SPONSORS WARRANTS PURCHASE AGREEMENT


 


This
SECOND Amended and restated SPONSORS WARRANTS PURCHASE AGREEMENT (this “Agreement”) is made as
of this 24th day of May, 2012 by and between Infinity Cross Border Acquisition Corporation, a British Virgin Islands business
company (the “Company”), having its principal place of business at 3 Azrieli Center (Triangle Tower)
42nd Floor, Tel Aviv, Israel, 67023 and the persons set forth on Exhibit A hereto (the “Sponsors”)
and amends and restates in its entirety that certain Amended Sponsors Warrants Purchase Agreement, effective December 30, 2011.


 


WHEREAS, the Company
desires to sell on a private placement basis (the “Offering”) an aggregate of 4,000,000 warrants (the
“Initial Warrants”) of the Company for a purchase price of $0.50 per Initial Warrant to
be governed by the Warrant Agreement (defined herein). Each Warrant is exercisable to purchase one ordinary share of the Company,
no par value (the “Ordinary Shares”), at an exercise price of $7.00 per Ordinary Share
during the period commencing on the date of the closing of the Company’s consummation of an acquisition, share exchange,
share reconstruction and amalgamation or contractual control arrangement with, purchase of all or substantially all of the assets
of, or any other similar business combination with one or more operating businesses or entities (a “Business Combination”)
and expiring on the third (3) anniversary of the Business Combination;


 


WHEREAS, the Sponsors
desire to purchase the Initial Warrants and the Company wishes to accept such subscription.


 


NOW, THEREFORE, in
consideration of the premises and the mutual covenants hereinafter set forth and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and the Sponsors hereby agree as follows:


 


1. Agreement to
Subscribe


 


1.1. Purchase and
Issuance of the Initial Warrants. For the aggregate sum of $2,000,000 (the “Purchase
Price”), upon the terms and subject to the conditions of this Agreement, each of the Sponsors hereby agrees to purchase
from the Company, and the Company hereby agrees to sell to the Sponsors, on the Closing Date (as defined in Section 1.2), the respective
number of Warrants as set forth in Exhibit A, for a purchase price of $0.50 per Warrant.


 


In addition to the
foregoing, each of the Sponsors hereby agrees to purchase up to an additional 381,818 Warrants (“Additional Warrants”
and together with the Initial Warrants, the “Warrants”) at $0.50 per Additional Warrant for a purchase price of $190,909
(“Additional Purchase Price”). The purchase and issuance of the Additional Warrants shall occur only in the event that
the underwriters’ 45-day over-allotment option (“Over-Allotment Option”) in the Offering is exercised
in full or part. The total number of Additional Warrants to be purchased hereunder shall be in the same proportion as the amount
of the Over-Allotment Option that is exercised. Each purchase of Additional Warrants shall occur simultaneously with the consummation
of any portion of the Over-Allotment Option.


 


1.2. Closing.
The closing (the “Closing”) of the Offering, shall take place at the offices of Ellenoff Grossman &
Schole LLP, 150 East 42nd Street, New York, New York, 10017 simultaneously with the consummation of the Company’s initial
public offering (“IPO”) of 5,000,000 units consisting of Ordinary Shares and warrants, or the consummation
of the exercise of an Over-Allotment Option (each a the “Closing Date”).



    	 



    	 	



    
 


1.3. Delivery of
the Purchase Price. At least one business day prior to the effective date of the Company’s registration statement relating
to the IPO, or the date of the exercise of the Over-Allotment Option, if any, each of the Sponsors agrees to deliver the Purchase
Price by certified bank check or wire transfer of immediately available funds denominated in United States Dollars to Ellenoff
Grossman & Schole LLP, which is hereby irrevocably authorized to deposit such funds on the applicable Closing Date to the trust
account which will be established for the benefit of the Company’s public shareholders, managed pursuant to that certain
Investment Management Trust Agreement to be entered into by and between the Company and a trustee and into which substantially
all of the proceeds of the IPO will be deposited (the “Trust Account”). If the IPO is not consummated
within 14 days of the date the Purchase Price is delivered to Ellenoff Grossman & Schole LLP, the Purchase Price shall be returned
to the Sponsors as soon as practicable by certified bank check or wire transfer of immediately available funds denominated in United
States Dollars without interest or deduction.


 


1.4. Delivery of
Warrant Certificate. Upon the applicable Closing Date after delivery of the Purchase Price in accordance with Section 1.3,
the Sponsors shall become irrevocably entitled to receive a warrant certificate representing the Warrants.


 


2. Representations
and Warranties of the Sponsors


 


Each of the Sponsors
represents and warrants to the Company that:


 


2.1. No Government
Recommendation or Approval. Each of the Sponsors understands that no United States federal or state agency or similar agency
of any other country has passed upon or made any recommendation or endorsement of the Company, the Offering, the Warrants or the
Ordinary Shares underlying the Warrants (the “Warrant Shares” and, collectively with the Warrants, the
“Securities”).


 


2.2. Organization. 
Each of the Sponsors is a Cayman Islands exempted company, validly existing and in good standing under the laws of the Cayman Islands
and possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.


 


2.3. Private
Offering. Each of the Sponsors represents that it is (a) an “accredited investor” as such term is defined in Rule
501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”) or (b) not
a “U.S. Person” as defined in Rule 902 of Regulation S (“Regulation S”) under the Securities Act. Subscriber
acknowledges that the sale contemplated hereby is being made in reliance on a private placement exemption to “Accredited
Investors” within the meaning of Section 501(a) of Regulation D under the Securities Act or similar exemptions under
state law or to a non-U.S. Person under Regulation S.


 


2.4. Authority.
This Agreement has been validly authorized, executed and delivered by each of the Sponsors and is
a valid and binding agreement enforceable in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, fraudulent conveyance or similar laws affecting the enforcement of creditors’ rights generally and
subject to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity). 


 


2.5. No Conflicts.
The execution, delivery and performance of this Agreement and the consummation by each of the Sponsors of the transactions contemplated
hereby do not violate, conflict with or constitute a default under (i) each of the Sponsors’ organizational documents,
(ii) any agreement, indenture or instrument to which each of the Sponsors is a party or (iii) any law, statute, rule or regulation
to which each of the Sponsors is subject, or any agreement, order, judgment or decree to which each of the Sponsors is subject.


 


2.6. No Legal Advice
from Company. Each of the Sponsors acknowledges it has had the opportunity to review this Agreement and the transactions contemplated
by this Agreement and the other agreements entered into between the parties hereto with such Sponsors’ own legal counsel
and investment and tax advisors. Except for any statements or representations of the Company made in this Agreement and the other
agreements entered into between the parties hereto, each of the Sponsors is relying solely on such counsel and advisors and not
on any statements or representations of the Company or any of its representatives or agents for legal, tax or investment advice
with respect to this investment, the transactions contemplated by this Agreement or the securities laws of any jurisdiction.



    	2



    	 



    
 


2.7. Access to
Information; Independent Investigation. Prior to the execution of this Agreement, each of the Sponsors has had the opportunity
to ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as
the finances, operations, business and prospects of the Company, and the opportunity to obtain additional information to verify
the accuracy of all information so obtained. In determining whether to make this investment, each of the Sponsors has relied solely
on each of the Sponsors’ own knowledge and understanding of the Company and its business based upon each of the Sponsors’
own due diligence investigation and the information furnished pursuant to this paragraph. Each of the Sponsors understands that
no person has been authorized to give any information or to make any representations which were not furnished pursuant to this
Section 2 and each of the Sponsors has not relied on any other representations or information in making its investment decision,
whether written or oral, relating to the Company, its operations and/or its prospects.


 


2.8. Reliance on
Representations and Warranties. Each of the Sponsors understands the Warrants are being offered and sold to it in reliance
on exemptions from the registration requirements under the Securities Act, and analogous provisions in the laws and regulations
of various states, and that the Company is relying upon the truth and accuracy of the representations, warranties, agreements,
acknowledgments and understandings of each of the Sponsors set forth in this Agreement in order to determine the applicability
of such provisions.


 


2.9. No Advertisements.
Each of the Sponsors is not subscribing for the Warrants as a result of or subsequent to any advertisement, article, notice or
other communication published in any newspaper, magazine, or similar media or broadcast over television or radio, or presented
at any seminar or meeting.


 


2.10. Legend.
Each of the Sponsors acknowledges and agrees the certificates evidencing the Warrants and the Warrant Shares shall bear a restrictive
legend (the “Legend”), in form and substance as set forth in Section 4 hereof, prohibiting the offer,
sale, pledge or transfer of the securities, except (i) pursuant to an effective registration statement covering these securities
under the Securities Act or (ii) pursuant to any other exemptions from the registration requirements under the Securities
Act and such laws which, in the opinion of counsel for the Company, is available.


 


2.11. Experience,
Financial Capability and Suitability. Each of the Sponsors is (i) sophisticated in financial matters and is able to evaluate
the risks and benefits of the investment in the Securities and (ii) able to bear the economic risk of his investment in the Securities
for an indefinite period of time because the Securities have not been registered under the Securities Act and therefore cannot
be sold unless subsequently registered under the Securities Act or an exemption from such registration is available. Each of the
Sponsors has substantial experience in evaluating and investing in transactions of securities in companies similar to the Company
so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own
interests. Each of the Sponsors must bear the economic risk of this investment until the Securities are sold pursuant to: (i) an
effective registration statement under the Securities Act; or (ii) an exemption from registration is available with respect to
such sale. Each of the Sponsors is able to bear the economic risks of an investment in the Securities and to afford a complete
loss each of the Sponsor’s investment in the Securities.


 


2.12. Investment
Purposes. Each of the Sponsors is purchasing the Securities solely for investment purposes, for each of the Sponsor’s
own account and not for the account or benefit of any other person, and not with a view towards the distribution or dissemination
thereof and each of the Sponsors have no present arrangement to sell the interest in the Securities to or through any person or
entity.



    	3



    	 



    
 


2.13. Restrictions
on Transfer. Each of the Sponsors acknowledges and understands the Warrants are being offered in a transaction not involving
a public offering in the United States within the meaning of the Securities Act. The Securities have not been registered under
the Securities Act, and, if in the future, any of the Sponsors decides to offer, resell, pledge or otherwise transfer the Securities,
such Securities may be offered, resold, pledged or otherwise transferred only (A) pursuant to an effective registration statement
filed under the Securities Act, (B) pursuant to an exemption from registration under Rule 144 promulgated under the Securities
Act (“Rule 144”), if available, or (C) pursuant to any other available exemption from the registration
requirements of the Securities Act, and in each case in accordance with any applicable securities laws of any state or any other
jurisdiction. Each of the Sponsors agrees that if any transfer of its Securities or any interest therein is proposed to be made,
as a condition precedent to any such transfer, such Sponsor may be required to deliver to the Company an opinion of counsel satisfactory
to the Company. Absent registration or another available exemption from registration, each of the Sponsors agrees it will not resell
the Securities. Each of the Sponsors further acknowledges that because the Company is a shell company, Rule 144 may not be available
to such Sponsor for the resale of the Securities until the one year anniversary following consummation of the initial Business
Combination of the Company, despite technical compliance with the requirements of Rule 144 and the release or waiver of any contractual
transfer restrictions.


 


3. Representations
and Warranties of the Company


 


The Company represents
and warrants to the Sponsors that:


 


3.1. Valid Issuance
of Share Capital. The total number of all classes of share capital which the Company has authority to issue is (i) an unlimited
number of Ordinary Shares and (ii) an unlimited number of preferred shares. As of the date hereof, the Company has issued 1,437,500
Ordinary Shares (of which 187,500 of such Ordinary Shares are subject to forfeiture as described in the registration statement
related to the Company’s IPO) and no preferred shares issued and outstanding. All of the issued share capital of the Company
has been duly authorized, validly issued, and are fully paid and non-assessable.


 


3.2. Title to Warrants.
Upon issuance in accordance with, and payment pursuant to, the terms hereof and the warrant agreement to be entered into with a
mutually agreeable warrant agent on or prior to the closing of the IPO (“Warrant Agreement”), as the
case may be, each of the Warrants and the Warrant Shares will be duly and validly issued, fully paid and non-assessable. Upon issuance
in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, as the case may be, the Sponsors will
have or receive good title to the Warrants, free and clear of all liens, claims and encumbrances of any kind, other than (i) any
transfer restrictions hereunder and under the other agreements contemplated hereby and (ii) transfer restrictions under federal
and state securities laws.


 


3.3. Organization
and Qualification. The Company has been duly incorporated and is validly existing as a British Virgin Islands business company
and has the requisite corporate power to own its properties and assets and to carry on its business as now being conducted.


 


3.4. Authorization;
Enforcement. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement and to issue the Warrants and the Warrant Shares in accordance with the terms hereof, (ii) the execution,
delivery and performance of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have
been duly authorized by all necessary corporate action and no further consent or authorization of the Company or its Board of Directors
or shareholders is required, and (iii) this Agreement constitutes, and upon the execution and delivery thereof, the Warrants
and the Warrant Agreement will constitute, valid and binding obligations of the Company enforceable against the Company in accordance
with their respective terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance,
moratorium, reorganization, or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and
remedies or by equitable principles of general application and except as enforcement of rights to indemnity and contribution may
be limited by federal and state securities laws or principles of public policy.



    	4



    	 



    
 


3.5. No Conflicts.
The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions contemplated
hereby do not (i) result in a violation of the Company’s Memorandum and Articles of Association, (ii) conflict
with, or constitute a default under any agreement, indenture or instrument to which the Company is a party or (iii) any law statute,
rule or regulation to which the Company is subject or any agreement, order, judgment or decree to which the Company is subject.
Other than any Securities and Exchange Commission, state or foreign securities filings which may be required to be made by the
Company subsequent to the Closing, and any registration statement which may be filed pursuant thereto, the Company is not required
under federal, state or local law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration
with, any court or governmental agency or self-regulatory entity in order for it to perform any of its obligations under this Agreement
or issue the Warrants or the Ordinary Shares issuable upon exercise thereof in accordance with the terms hereof.


 


4. Legends


 


4.1. Legend.
The Company will issue the Warrants, and when issued, the Warrant Shares, purchased by the Sponsors, in the names of the respective
Sponsors. The Securities will bear the following Legend and appropriate “stop transfer” instructions:


 


THESE SECURITIES (i) HAVE NOT BEEN REGISTERED
UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND THESE SECURITIES MAY NOT BE
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE SECURITIES
ACT, (B) TO A NON-U.S. PERSON IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES
ACT, (C) PURSUANT TO THE RESALE LIMITATIONS SET FORTH IN RULE 905 OF REGULATIONS S UNDER THE SECURITIES ACT, (D) PURSUANT TO AN
EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF AVAILABLE) OR (E) PURSUANT TO ANY OTHER EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES OR ANY OTHER JURISDICTION. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS
IN COMPLIANCE WITH THE SECURITIES ACT.


 


IN ADDITION, THE SECURITIES REPRESENTED
BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS AFTER THE DATE UPON WHICH Infinity
Cross border Acquisition Corporation (THE “COMPANY”) COMPLETES ITS INITIAL BUSINESS COMBINATION
(AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2
OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.



    	5



    	 



    
 


SECURITIES EVIDENCED BY THIS CERTIFICATE
AND THE ordinary shares OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL
BE ENTITLED TO REGISTRATION RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.


 


4.2. Sponsors’
Compliance. Nothing in this Section 4 shall affect in any way each of the Sponsors’ obligations and agreements to
comply with all applicable securities laws upon resale of the Securities.


 


4.3. Company’s
Refusal to Register Transfer of the Securities. The Company shall refuse to register any transfer of the Securities, if in
the sole judgment of the Company such purported transfer would not be made (i) pursuant to an effective registration statement
filed under the Securities Act, or (ii) pursuant to an available exemption from the registration requirements of the Securities
Act.


 


4.4. Registration
Rights. Each of the Sponsors will be entitled to certain registration rights which will be governed by a registration rights
agreement (“Registration Rights Agreement”) to be entered into with the Company on or prior to the closing
of the IPO.


 


5. Lockup


 


Each of the Sponsors
acknowledges and agrees that the Warrants shall not be transferable, saleable or assignable until the consummation of a Business
Combination, except to permitted transferees (as defined in Section 2 of the Warrant Agreement).


 


6. Securities Laws
Restrictions


 


Each of the Sponsors
agrees not to sell, transfer, pledge, hypothecate or otherwise dispose of all or any part of the Securities unless, prior thereto
(a) a registration statement on the appropriate form under the Securities Act and applicable state securities laws with respect
to the Securities proposed to be transferred shall then be effective or (b) the Company shall have received an opinion from
counsel reasonably satisfactory to the Company, that such registration is not required because such transaction complies with the
Securities Act and the rules promulgated by the Securities and Exchange Commission thereunder and with all applicable state securities
laws.


 


7. Waiver of Liquidation
Distributions


 


In connection with
the Securities purchased pursuant to this Agreement, each of the Sponsors hereby waives any and all right, title, interest or claim
of any kind in or to any distributions from the Trust Account. In no event will a Sponsor have the right to exercise any Warrants
prior to the consummation of a Business Combination.


 


8. Rescission Right
Waiver and Indemnification 


 


8.1. Rescission
Waiver. Each of the Sponsors understands and acknowledges that an exemption from the registration requirements of the Securities
Act requires there be no general solicitation of Sponsors of the Warrants. In this regard, if the Offering were deemed to be a
general solicitation with respect to the Warrants, the offer and sale of such Warrants may not be exempt from registration and,
if not, the Sponsors may have a right to rescind its purchase of the Warrants. In order to facilitate the completion of the Offering
and in order to protect the Company, its shareholders and the Trust Account from claims that may adversely affect the Company or
the interests of its shareholders, each of the Sponsors hereby agrees to waive, to the maximum extent permitted by applicable law,
any claims, right to sue or rights in law or arbitration, as the case may be, to seek rescission of its purchase of the Warrants
as a result of the issuance of the Warrants being deemed to be in violation of Section 5 of the Securities Act. Each of the Sponsors
acknowledges and agrees this waiver is being made in order to induce the Company to sell the Warrants to the Sponsors. Each of
the Sponsors agrees the foregoing waiver of rescission rights shall apply to any and all known or unknown actions, causes of action,
suits, claims or proceedings (collectively, “Claims”) and related losses, costs, penalties, fees, liabilities
and damages, whether compensatory, consequential or exemplary, and expenses in connection therewith, including reasonable attorneys’
and expert witness fees and disbursements and all other expenses reasonably incurred in investigating, preparing or defending against
any Claims, whether pending or threatened, in connection with any present or future actual or asserted right to rescind the purchase
of the Warrants hereunder or relating to the purchase of the Warrants and the transactions contemplated hereby.



    	6



    	 



    
 


8.2. No Recourse
Against Trust Account. Each of the Sponsors agrees not to seek recourse against the Trust Account for any reason whatsoever
in connection with its purchase of the Warrants or any Claim that may arise now or in the future.


 


8.3. Section 8
Waiver. Each of the Sponsors agrees that to the extent any waiver of rights under this Section 8 is ineffective as a matter
of law, each of the Sponsors have offered such waiver for the benefit of the Company as an equitable right that shall survive any
statutory disqualification or bar that applies to a legal right. Each of the Sponsors acknowledges the receipt and sufficiency
of consideration received from the Company hereunder in this regard.


 


9. Terms of the
Warrant


 


The Warrants shall
be substantially identical to the warrants included in the units offered in the IPO as set forth in the Warrant Agreement, except
the Warrants: (i) will be subject to the transfer restrictions described herein, (ii) are being purchased pursuant to an exemption
from the registration requirements of the Securities Act and will become freely tradable only after certain conditions are met
or the resale of the Warrants is registered under the Securities Act, (iii) will be non-redeemable so long as they are held by
the Sponsors or any of their permitted transferees and (iv) are exercisable for cash or on a “cashless” basis
if held by the Sponsors or any of their permitted transferees.


 


10. Governing Law;
Jurisdiction; Waiver of Jury Trial


 


This Agreement shall
be governed by and construed in accordance with the laws of the British Virgin Islands for agreements made and to be wholly performed
within such country. The parties hereto hereby waive any right to a jury trial in connection with any litigation pursuant to this
Agreement and the transactions contemplated hereby.


 


11. Assignment;
Entire Agreement; Amendment


 


11.1. Assignment.
Neither this Agreement nor any rights hereunder may be assigned by any party to any other person other than by Sponsors, without
the prior consent of the Company, to one or more persons agreeing to be bound by the terms hereof. Upon such assignment by a Sponsor,
the assignee(s) shall become parties to this agreement and have the rights and obligations provided for herein to the extent of
such assignment.


 


11.2. Entire Agreement.
This Agreement sets forth the entire agreement and understanding between the parties as to the subject matter hereof and supersedes
any and all prior discussions, agreements and understandings of any and every nature.


 


11.3. Amendment.
Except as expressly provided in this Agreement, neither this Agreement nor any term hereof may be amended, waived, discharged or
terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge
or termination is sought.


 


11.4. Binding upon
Successors. This Agreement shall be binding upon and inure to the benefit of the parties hereto and to their respective heirs,
legal representatives, successors and permitted assigns.



    	7



    	 



    
 


12. Notices; Indemnity


 


12.1 Notices.
All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party’s
address set forth herein or to such other address as a party may designate by notice hereunder, and shall be either (a) delivered
by hand, (b) sent by overnight courier, or (c) sent by certified mail, return receipt requested, postage prepaid. All notices,
requests, consents and other communications hereunder shall be deemed to have been given either (i) if by hand, at the time of
the delivery thereof to the receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on
the next business day following the day such notice is delivered to the courier service, or (iii) if sent by certified mail, on
the fifth business day following the day such mailing is made.


 


12.2. Indemnification.
Each party shall indemnify the other party against any loss, cost or damages (including reasonable attorney’s fees and expenses)
incurred as a result of such party’s breach of any representation, warranty, covenant or agreement set forth in this Agreement.


 


13. Counterparts


 


This Agreement may
be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both
parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission or any
other form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.


 


14. Survival; Severability


 


14.1. Survival.
The representations, warranties, covenants and agreements of the parties hereto shall survive the Closing and one (1) year following
the consummation of an initial Business Combination.


 


14.2. Severability.
In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable
or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability
shall be effective if it materially changes the economic benefit of this Agreement to any party.


 


15. Headings


 


The titles and subtitles
used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.


 


16. Construction


 


The parties hereto
have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of intent or interpretation
arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of proof will
arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. The words “include,”
“includes,” and “including” will be deemed to be followed by “without limitation.”
Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form
will be construed to include the plural and vice versa, unless the context otherwise requires. The words “this Agreement,”
“herein,” “hereof,” “hereby,” “hereunder,” and words
of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties
hereto intend that each representation, warranty, and covenant contained herein will have independent significance. If any party
hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another
representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which
such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first
representation, warranty, or covenant.


 


[remainder of page intentionally left blank]



    	8



    	 



    
 


This subscription is accepted by the Company as of the date
first written above.


 


 


	 	INFINITY CROSS BORDER ACQUISITION
CORPORATION
	 	 	 
	 	By:	/s/ Mark Chess
	 	 	 
	 	Name:	Mark Chess
	 	Title:	Vice President


 


 


 


Accepted and agreed this


May 24, 2012


 


INFINITY I-CHINA FUND (CAYMAN), L.P. 


 


By: /s/ Avishai Silvershatz


	Name:   Avishai Silvershatz
	Title:    Managing Partner


 


INFINITY I-CHINA FUND (ISRAEL), L.P. 


 


By: /s/ Avishai Silvershatz


	Name:   Avishai Silvershatz
	Title:    Managing Partner


 


INFINITY I-CHINA FUND (ISRAEL 2), L.P. 


 


By: /s/ Avishai Silvershatz


	Name:   Avishai Silvershatz
	Title:    Managing Partner


 


INFINITY I-CHINA FUND (ISRAEL 3), L.P. 


 


By: /s/ Avishai Silvershatz


	Name:   Avishai Silvershatz
	Title:    Managing Partner


 






    	9



    	 



    
 



Exhibit A


 


 


	Sponsor	
        Number of Warrants

         

	Infinity I-China Fund (Cayman), L.P.  	933,600
	
        Infinity I-China Fund (Israel), L.P.

         
	
         

        476,400

	
        Infinity I-China Fund (Israel 2), L.P.

         
	
         

        407,200

	
        Infinity I-China Fund (Israel 3), L.P.

         
	
         

        182,800

	Total	2,000,000


 


 


 



    	10